In the field of pharmaceutical packaging,Oral medicinal plastic bottlesAs the "last line of defense" for direct contact with drugs, its safety and reliability are directly related to drug quality, patient medication safety, and efficacy stability. Compared to traditional glass packaging, plastic bottles have become the mainstream packaging form for oral preparations such as tablets, capsules, granules, etc. (accounting for more than 70% of the oral solid preparation packaging market) due to their advantages of lightweight, strong impact resistance, low cost, and good sealing. However, the differences in chemical migration, barrier properties, and production process fluctuations of plastic materials may also bring aboutHarmful substance migration, drug moisture absorption and deterioration, sealing failureWaiting for risks. Therefore, how to ensure the safety (no harmful substance migration) and reliability (barrier, sealing, weather resistance standards) of oral pharmaceutical plastic bottles through material selection, process optimization, and quality control is the core issue of the pharmaceutical packaging industry.

1、 Core safety requirements for oral pharmaceutical plastic bottles: from "material compliance" to "safety of use"

The safety of oral medicinal plastic bottles needs to meet the requirementsMaterial safety itself, production process safety, and usage process safetyThe three dimensions are based on strict regulatory standards both domestically and internationally, such as the Chinese YBB standard, the US FDA 21 CFR 177, and the EU EP 3.1.6.

　　1. Material Compliance: Red Line for Prohibited and Restricted Substances​

The safety of plastic bottles first depends on the choice of raw materials. The commonly used polymer materials for oral pharmaceutical plastic bottles includePolyethylene (PE), polypropylene (PP), polyester (PET), polyvinyl chloride (PVC)Wait, the following requirements must be met:

　　Prohibited substancesProhibit the use of phthalates (plasticizers such as DEHP), bisphenol A (BPA, endocrine disruptors), heavy metals (lead, cadmium, mercury), fluorescent whitening agents, and other harmful substances to the human body;

　　Restricted SubstancesMonomer residues (such as ethylene glycol residues in PET ≤ 0.5%) and catalyst residues (such as peroxide residues in PE ≤ 0.1%) need to be strictly controlled to avoid migration into the drug;

　　Compatibility requirementsThe material needs to have no interaction with the drug (such as not reacting with acidic/alkaline drugs, not adsorbing the main drug components). For example, oral liquids containing ethanol should use PP bottles with good solvent resistance (PE may be swollen by ethanol), while tablets with strong moisture absorption (such as traditional Chinese medicine extract tablets) should use PET bottles with strong barrier properties (PE has high moisture permeability and can easily cause drug deliquescence).

　　2. Production process safety: avoid "secondary pollution"​

The production process of plastic bottles (such as injection molding, blow molding, printing) must comply with GMP (Good Manufacturing Practice) requirements, with a focus on controlling:

　　cleanlinessThe production environment must meet Class D or higher clean area standards (dust particles ≤ 3520000/m ³, microorganisms ≤ 200CFU/m ³) to avoid dust and microbial contamination of the bottle body;

　　Additive controlProcessing aids (such as lubricants, antioxidants) should be selected from food grade/pharmaceutical grade (such as silica lubricants), and the addition amount should be ≤ 0.5% (to avoid migration);

　　printing securityThe ink used for bottle body printing must comply with YBB standards (such as alcohol soluble ink replacing benzene soluble ink), and the printing layer must be tightly adhered to the bottle body (without the risk of detachment) to avoid the migration of organic solvents (such as toluene) in the ink to the drug.

　　3. Safe use process: risk prevention and control throughout the entire lifecycle​

During the storage, transportation, and use of drugs, plastic bottles need to resistLight, temperature, humidity, mechanical stressWaiting for external factors to ensure stable drug quality:

　　barrierIt is necessary to block water vapor (to prevent moisture absorption), oxygen (to prevent oxidation), and light (to prevent the decomposition of photosensitive drugs). For example, photosensitive drugs such as vitamin C tablets need to use brown PET bottles (light transmittance ≤ 10%);

　　sealing performanceThe fit between the bottle cap and the bottle mouth should be tight (such as using a screw cap and aluminum foil gasket) to avoid the volatilization of drugs or the invasion of external pollutants (such as dust and microorganisms);

　　耐温性To withstand temperature fluctuations during storage (-20 ℃~50 ℃) and transportation (high temperature exposure), and avoid deformation or release of harmful substances (such as PVC may release HCl at high temperatures).

2、 Reliability Design: Collaborative Guarantee from "Material Performance" to "Structural Optimization"

The reliability of oral medicinal plastic bottles needs to be verified throughMaterial selection, structural design, and process controlThe core goal of achieving synergy in three aspects is to ensure that drugs do not deteriorate or become ineffective within their expiration date (usually 1-3 years).

　　1. Accurate matching of material properties​

The physical and chemical properties of different drugs (such as hygroscopicity, volatility, chemical activity) have significant differences in the performance requirements of packaging materials, and targeted selection is needed:

　　Moisture absorbing drugs (such as traditional Chinese medicine powder, effervescent tablets): Priority selectionHigh density polyethylene (HDPE)orPET(Moisture permeability: HDPE ≈ 0.5g/(m ² · d), PET ≈ 0.2g/(m ² · d), much lower than the 2-5 g/(m ² · d) of LDPE);

　　Oxidizing drugs (such as fat soluble vitamins): SelectPET(Oxygen permeability ≈ 0.05cm ³/(m ² · d · atm), about 1/10 of PE), or composite film (such as PET/aluminum foil/PE) to further enhance barrier properties;

　　Corrosive drugs (such as aspirin enteric coated tablets, hydrolyzed when wet): SelectPP(Strong chemical resistance, stable within pH range of 1-14) orCycloolefin copolymer (COC)(Low water absorption, high transparency);

　　Children's safety needs: SelectAnti opening bottle capTo open (such as pressing the rotating cover), a force of ≥ 5N must be applied to prevent children from accidentally taking it.

　　2. Detail optimization of structural design​

The structural design of plastic bottles directly affects their sealing, mechanical strength, and ease of use

　　Bottle mouth designThe use of "wide mouth" or "narrow mouth" requires matching the drug form (such as using wide mouth bottles for granules to facilitate drug retrieval, and using narrow mouth bottles for tablets to reduce volatilization); The tolerance of the inner diameter of the bottle mouth should be ≤± 0.1mm to ensure a tight fit with the bottle cap;

　　Bottle body structureBy strengthening the reinforcement design, the anti drop performance can be improved (such as no rupture when dropped from a height of 1.5m); Thin walled bottles (wall thickness ≤ 0.5mm) can reduce material usage, but their pressure resistance needs to be verified through CAE simulation (such as stacking 10 layers without deformation);

　　sealed structureSelection of bottle cap inner padfoamed siliconeoraluminum foil composite film(Compression deformation ≤ 20%, ensuring that it remains sealed even after multiple openings); The thread design must comply with ISO 8317 standard (such as pitch 1.2mm, profile angle 60 °) to avoid thread slippage.

　　3. Stability guarantee of process control​

The stability of the production process directly determines the consistency and reliability of plastic bottles, with key steps including:

　　forming processInjection molding requires controlling the melt temperature (such as 180-220 ℃ for PP) and mold temperature (40-80 ℃) to avoid internal stress causing bottle cracking; Blow molding (such as PET bottles) requires precise control of the stretch ratio (3:1 longitudinally and 2:1 transversely) to ensure barrier properties and transparency;

　　Sterilization compatibilityIt is necessary to tolerate common sterilization methods for drug packaging, such as ethylene oxide sterilization and radiation sterilization. For example, PE bottles can withstand 25kGy of gamma ray irradiation (without free radical breakage), while PVC bottles will turn yellow and brittle after irradiation;

　　dimensional accuracyThe tolerance of bottle height, bottle diameter, and wall thickness should be ≤± 0.2mm (monitored in real-time through an online visual inspection system) to avoid inaccurate filling or sealing failure due to dimensional deviations.

3、 Quality inspection and supervision: controlling the "safety bottom line" throughout the entire chain

To ensure the safety and reliability of plastic bottles for oral medication, it is necessary toFull chain quality inspection of raw materials, processes, finished products, and usageAnd comply with the audit requirements of regulatory agencies such as the National Medical Products Administration and FDA.

　　1. Raw material testing: eliminating risks from the source​

　　Material identificationVerify the material type (such as the C-H characteristic peak of PE and the ester peak of PET) through infrared spectroscopy (FTIR) to avoid mixing;

　　Impurity controlUse gas chromatography-mass spectrometry (GC-MS) to detect monomer residues (such as ethylene glycol in PET ≤ 0.5%) and solvent residues (such as acrylonitrile in injection molding process ≤ 0.01%);

　　生物安全性Conduct cell toxicity tests (MTT assay) and skin sensitization tests (guinea pig test) according to the Chinese Pharmacopoeia to ensure no teratogenic or carcinogenic risks.

　　2. Process detection: monitoring production stability​

　　Cleanliness monitoringRegularly detect dust particles (laser particle counter) and microorganisms (settling bacteria method) in the production environment to ensure compliance with D-level clean area standards;

　　Process parameter monitoringReal time recording of injection pressure (such as PE 80~120MPa) and blow molding temperature (PET 280~320 ℃) through PLC system, with automatic alarm when exceeding the threshold;

　　online detectionUsing a machine vision system (resolution ≥ 0.01mm) to detect bottle defects (such as bubbles, scratches, deformation) and eliminate non-conforming products (pass rate ≥ 99.5%).

　　3. Finished product testing: verifying key performance indicators​

　　物理性能Measure tensile strength (PE ≥ 15MPa, PET ≥ 50MPa), drop ball impact strength (no rupture at a height of 1.5m), and sealing performance (negative pressure of 0.08MPa maintained for 5 minutes without leakage);

　　barrier performanceMeasure the water vapor transmission rate (WVTR) using a moisture permeability meter (GB/T 1037) and the oxygen transmission rate (OTR) using an OTR meter (GB/T 19789);

　　Chemical safetyAccording to YBB 00172002Dissolution test(Simulating drug solution immersion, detecting heavy metals ≤ 1ppm, pH change ≤ 1.0)Non volatile matter test(Evaporation residue of soaking solution ≤ 10mg);

　　Compatibility testPlaced together with the drug under accelerated testing conditions (40 ℃/75% RH, 6 months), with a decrease in drug content of ≤ 5% and an increase in related substances of ≤ 0.5%.

　　4. Supervision and traceability​

　　Registration and filingPlastic bottles need to obtain a "Drug Packaging Material Registration Certificate" issued by the National Medical Products Administration (such as "National Medical Products Administration Approval Letter Package Letter XXXX"), indicating the applicable drug type (such as tablets, capsules);

　　Batch traceabilityEach batch of products must retain samples (≥ 500 pieces), recording the production date, raw material batch number, and process parameters, with a shelf life of ≥ 1 year after the expiration date of the drug;

　　spot checkAccept surprise inspections by regulatory agencies (such as the inspection of 10 pharmaceutical packaging material companies by the National Medical Products Administration in 2023, which found that 3 companies were ordered to rectify due to "exceeding microbial standards in clean areas").

4、 Development Trend: Upgrading from "Security Compliance" to "Functional Innovation"

With the increasing demand for drug quality in the pharmaceutical industry, plastic bottles for oral use are moving towardsHigh barrier, intelligent, and greenDirection evolution:

　　1. High barrier materials: addressing the challenges of new drugs​

Biological agents (such as monoclonal antibodies and oral vaccine formulations) require high barrier properties for packaging (oxygen permeability ≤ 0.01cm ³/(m ² · d · atm)), promotingMulti layer composite plastic bottle(such as PET/PA/PE) orCycloolefin polymer (COC)/cyclic olefin copolymer (COP)Its barrier properties are 10-100 times that of ordinary PET.

　　2. Intelligent packaging: improving medication adherence​

integrationRFID chiporQR codeThe plastic bottle can achieve "anti-counterfeiting traceability+medication reminder" (such as scanning the bottle's QR code to obtain medication time and remaining dose);Temperature sensitive color changing labelIf the label turns red when the temperature exceeds 25 ℃, it can warn of improper storage of drugs.

　　3. Green materials: practicing sustainable development​

　　recyclable materialsPromote single material plastic bottles (such as 100% PP) to avoid the recycling problem of multi-layer composite materials;

　　Biobased plasticsUsing biodegradable materials such as PLA (polylactic acid) and PHA (polyhydroxyalkanoates) (their compatibility with drugs needs to be verified);

　　Reduced designBy thinning (reducing wall thickness from 0.8mm to 0.5mm), material usage is reduced (reducing weight by 30% per bottle) and carbon emissions are minimized.

　　ConclusionOral medicinal plastic bottles are the "guardians" of drug safety and efficacy, and their safety and reliability need to be jointly guaranteed through material compliance, process optimization, and full chain quality control. In the future, with the development of new materials and technologies, plastic bottles will be further upgraded to "safer, smarter, and greener", providing solid support for patient medication safety and high-quality development of the pharmaceutical industry.